Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Alessandro Leonetti(University of Parma), Elisa Giovannetti(University of Pisa), Giulia Mazzaschi(University of Parma), Federico Quaini(University of Parma), Marcello Tiseo(University of Parma), Birgit M. M. Wever(Dutch Cancer Society), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Yehuda G. Assaraf(Technion – Israel Institute of Technology)
Cited by 198
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
|British Journal of Cancer|2019|1.3k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642